Tamsulosin Hydrochloride Capsule
Product Images NDC 43063-947

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 43063-947). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063947 Label (43063947)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by PD-Rx Pharmaceuticals, Inc. The label indicates a 30-capsule package with dosage form as oral capsules. It includes NDC 43063-947-30, lot number C22E85, and expiration date 03/2024. The label also features a barcode, dosing instructions area, and a warning to keep out of reach of children.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph depicting mean plasma concentrations of Tamsulosin Hydrochloride (0.4 mg capsules) over time in hours, comparing results under fasted and fed conditions. The y-axis represents plasma concentration in ng/mL, and the x-axis represents time from 0 to 36 hours post-dose, with separate curves for fasted and fed states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph depicting the mean change from baseline in total AUA symptom score over treatment duration in weeks. It compares three treatments: Tamsulosin Hydrochloride 0.8 mg, Tamsulosin Hydrochloride 0.4 mg, and placebo. The y-axis shows mean change scores, and the x-axis shows treatment duration from 0 to 13 weeks plus LOCF (last observation carried forward). The graph shows decreasing symptom scores over time for all groups, with the 0.8 mg dose showing the greatest change.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2' showing mean change on the y-axis and duration of treatment in weeks on the x-axis. It compares three treatments: 0.8 mg and 0.4 mg doses versus placebo over 13 weeks, indicating symptom score reductions over time with numerical details on sample sizes below the x-axis.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled "Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1" showing mean changes over treatment duration in weeks. It compares three groups: 0.8 mg dose (circle markers), 0.4 mg dose (triangle markers), and placebo (square markers). The y-axis represents mean change in mL/sec, and the x-axis shows weeks of treatment from baseline up to 13 and last observation carried forward (LOCF).*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph illustrating the mean increase in peak urine flow rate (mL/sec) over duration of treatment in weeks. The graph compares three treatment groups with different dosages of Tamsulosin Hydrochloride (0.8 mg and 0.4 mg) and a placebo group, showing their respective urine flow rate changes throughout the study period.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular arrangement, including aromatic rings, functional groups, and the hydrochloride (HCl) component, as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.